Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.48 |
| ▸ | PGR | P06401 | 12/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168183 | 0.80 | ALDH1A1 (0.49) | KDM4ETP53L3MBTL1ALDH1A1GLA | |
| SCHEMBL173483 | 0.80 | ALDH1A1 (0.49) | NR3C2KDM4ETP53ALDH1A1GLA | |
| SCHEMBL3224585 | 0.77 | NR3C1 (0.48) | NR3C1PGRNR3C2ITGAVL3MBTL1 | |
| SCHEMBL3210497 | 0.76 | KDM4E (0.72) | NR3C1KDM4EITGAVALDH1A1 | |
| SCHEMBL31086845 | 0.76 | KDM4E (0.72) | NR3C1KDM4EITGAVALDH1A1 | |
| SCHEMBL3219746 | 0.74 | NR3C1 (0.50) | NR3C1PGRNR3C2L3MBTL1 | |
| SCHEMBL3216794 | 0.71 | NR3C1 (0.52) | NR3C1PGRNR3C2L3MBTL1 | |
| SCHEMBL31086802 | 0.71 | MMP1 (0.53) | KDM4E | |
| SCHEMBL28909750 | 0.70 | NR3C1 (0.47) | NR3C1PGRNR3C2KDM4EL3MBTL1 | |
| SCHEMBL28606962 | 0.69 | NR3C1 (0.46) | NR3C1PGRNR3C2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2136811-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008124745-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124745-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885PGR 88/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.